Prognostic factors of oligometastatic non-small-cell lung cancer following radical therapy: a multicentre analysis by Opitz, Isabelle et al.








Prognostic factors of oligometastatic non-small-cell lung cancer following
radical therapy: a multicentre analysis
Opitz, Isabelle ; Patella, Miriam ; Payrard, Loic ; Perentes, Jean Yannis ; Inderbitzi, Rolf ; Gelpke,
Hans ; Schulte, Sandra ; Diezi, Maja ; Gonzalez, Michel ; Krueger, Thorsten ; Weder, Walter
Abstract: OBJECTIVES Patients with oligometastatic non-small-cell lung cancer (NSCLC) may benefit
from therapy with curative intent. Our goal was to identify prognostic factors related to better prog-
nosis in a multicentre analysis of patients who underwent surgery of primary tumours in combination
with radical treatment of all metastatic sites. METHODS We retrospectively reviewed the records of
oligometastatic patients who underwent resection of primary tumours at 4 centres (August 2001-February
2018). Oligometastasis was defined as ฀5 synchronous metastases in ฀2 organs. Radical metastatic treat-
ment was surgery, radiotherapy or a combination. The Cox proportional hazards model was used for
identification of prognostic factors on overall survival. RESULTS We treated 124 patients; 72 (58%) were
men, mean age 60 ± 9.8 years, with 87 (70%) adenocarcinoma. Sixty-seven (54%) patients had positive
pathologic-N stage (pN). Brain metastases were most common (n = 76; 61%) followed by adrenal (n =
13; 10%) and bone (n = 12; 10%). Systemic therapy was administered in 101 (82%) patients. Median
follow-up was 60 months [95% confidence interval (CI) 41-86]. Thirty- and 90-day mortality rates were
0 and 2.4%, respectively. One-, 2-, and 5-year overall survival were 80%, 58% and 36%, respectively.
Cox regression analysis showed that patients ฀60 years [hazard ratio (HR) 0.41, 95% CI 0.24, 0.69; P =
0.001] and patients with pN0 (HR 0.38, 95% CI 0.21-0.69; P = 0.002) had a significant survival benefit.
The presence of bone metastases negatively affected survival (HR 2.53, 95% CI 1.05-6.09; P = 0.04).
CONCLUSIONS Treatment with curative intent of selected oligometastatic NSCLC, including resection
of the primary tumour, can be performed safely and with excellent 5-year survival rates, especially in
younger patients with pN0 disease.
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Patients with oligometastatic non-small cell lung cancer (NSCLC) may benefit from therapy with 31 
curative intent. We aimed to identify prognostic factors related to better prognosis, in a multicenter 32 
analysis of patients who underwent surgery of primary tumors, in combination with radical treatment of 33 
all metastatic sites. 34 
Methods  35 
We retrospectively reviewed the records of oligometastatic patients who underwent resection of primary 36 
tumor at four centers, (08/2001-02/2018). Oligometastasis was defined as ≤5 synchronous metastases in 37 
≤2 organs. Radical metastatic treatment was surgery, radiotherapy or a combination. Cox proportional 38 
hazards model was used for identification of prognostic factors on overall survival (OS). 39 
Results 40 
We treated 124 patients; 72 (58%) were male, mean age 60±9.8 years, with 87 (70%) adenocarcinoma. 41 
Sixty-seven (54%) had pathological positive nodal status (pN). Brain metastasis was most common 42 
(n=76; 61%) followed by adrenal (n=13;10%) and bone (n=12;10%). Systemic therapy was 43 
administered in 101 (82%) patients. Median follow-up was 60 months (95% CI: 41, 86). 44 
Thirty- and 90-day mortality were 0 and 2.4% respectively. One-, 2-, and 5-year OS was 80%, 58%, and 45 
36% respectively. Cox regression analysis showed that patients ≤60 years (HR: 0.41, 95% CI: 0.24, 46 
0.69, p=0.001) and patients with pN0 (HR 0.38, 95% CI: 0.21, 0.69, p=0.002) had a significant survival 47 
benefit. The presence of bone metastasis negatively affected survival (HR: 2.53, 95% CI: 1.05, 6.09, 48 
p=0.04). 49 
Conclusions  50 
Treatment with curative intent of selected oligometastatic NSCLC, including resection of the primary 51 
tumor, can be performed safely and with excellent 5-year survival, especially in younger patients with 52 
pN0 disease. 53 
 54 




Lung cancer is the leading cause of cancer-related death worldwide with poor survival for the 57 
metastatic stage. However, since Hellman and Weichselbaum described the concept of oligometastatic 58 
state in 1995(1), the interest in the heterogeneity of stage IV non-small cell lung cancer (NSCLC) has 59 
exponentially grown within the scientific community. Current European(2) and American(3) guidelines 60 
indicate local ablative treatment for primaries and metastatic site in selected patients. However, the 61 
evidence mostly results from case-series and is therefore considered low grade. Two prospective trials 62 
lead by radio-oncologists(4,5) reported a significant improved progression-free survival (PFS) and 63 
overall survival (OS) with the use of local therapies to all disease sites. Surgery has been part of the 64 
treatment strategy in a small percentage of patients in one trial(4), while the other only focused on the 65 
use of stereotactic body radiotherapy (SBRT). Nevertheless, surgery has been used in oligometastatic 66 
NSCLC for more than 40 years, with a broad range of results(6). 67 
According to the Swiss Cancer Report 2015(7), in Switzerland lung cancer accounts for 11.8% 68 
of all types of cancer among men and for 8.5% among women. Between 2008 and 2012 an average of 69 
some 2500 men and 1500 women were diagnosed with lung cancer each year. Median age at diagnosis 70 
is 70 year for man and 69 for woman, with an incidence rate that rise up between 75 and 79 year, then 71 
decline. 72 
In this study, we analyzed the long-term experience of four SWISS surgical centers with the aim 73 
to identify prognostic factors associated with better outcome for patients with oligometastatic disease 74 
treated with curative intent.  75 
 76 
PATIENTS AND METHODS 77 
Patients’ institutional databases of four surgical centers in Switzerland (Universitätsspital 78 
Zürich, Ospedale Regionale di Bellinzona e Valli, Centre Hospitalier Universitaire Vaudois of 79 
Lausanne, Kantonsspital Winterthur) were screened for patients treated for metastatic NSCLC between 80 
2001 and 2018. The centers included are two university hospitals and two cantonal hospitals, accounting 81 
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for the larger number of lung cancer patients/year visited in each canton(8). Local ethics committees 82 
approved the study (2019-00636), written consent was obtained from living patients and waived for the 83 
deceased ones. We included patients who fulfilled the following criteria: age ≥ 18 years; histologically 84 
confirmed NSCLC with ≤ 5 synchronous metastasis in ≤ 2 organs; radical surgical treatment of the 85 
primary tumor ± neoadjuvant/adjuvant therapy; radical treatment of all metastatic sites. For metastasis 86 
treated with radiotherapy, morphological/metabolic criteria were used to confirm complete response, for 87 
brain metastasis, the radicality was confirmed by neuro-radiologist based on MRI imaging. Surgical 88 
resections performed with palliative or diagnostic intent were excluded. All patients were discussed in 89 
multidisciplinary tumor boards for the indication of surgical and-or adjuvant as well as the therapy 90 
sequence. 91 
We included a small cohort (21 cases) of patients described previously(9). Patients were 92 
uniformly re-staged according to the American Joint Committee on Cancer (AJCC) 7th edition; therefore, 93 
we excluded from the previous series the cases with synchronous nodules in same lung within different 94 
lobes. Patients with incomplete data about surgical indication, intent of treatment and patients who did 95 
not complete the radical management were excluded from the analysis. 96 
 Primary end point of the study was overall survival (OS) defined as the time from the first 97 
treatment (lung surgery, metastasis ablation or neoadjuvant treatment) to the date of death, with living 98 
patients censored at the date of last follow-up. Secondary end point was the progression-free survival 99 
(PFS) defined as the time from the first treatment to the date of first progression, local or distant. Follow-100 
up information were obtained from electronic records or, if absent, from telephonic interviews with 101 
patients and relatives. 102 
The following variables were collected and considered for analysis: gender, age (≤ 60 vs > 60 years), , 103 
pathological T-stage (pT1-2 vs 3-4), pathological N-stage (pN0 vs 1-2 and pN0-1 vs 2), metastasis 104 
location (brain vs other, adrenal vs other, bone vs other, lung vs other), number of metastasis (single vs 105 
multiple), single vs multiple organs involved, neoadjuvant and adjuvant therapy, resection margins (R0 106 
vs R+), metastasis treatment (surgery vs no surgery, combined treatment vs single strategy), timing of 107 
treatment (metastasis first vs primary first). 108 
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Median OS and PFS were estimated by the Kaplan–Meier method. Differences in survival rates were 109 
described by median OS, hazard ratio (HR) and 95% confidence intervals (CIs) and compared by the 110 
log-rank test. Predictors’ selection was based on clinical knowledge, the Cox regression model was 111 
assessed for multivariable survival analyses. Backward elimination was performed with a p-value 112 
criterion of 0.15. P-values were considered significant below 0.05. To avoid bias related to collinearity, 113 
highly correlated variables were tested separately and the Akaike information criterion (AIC) was used 114 
to estimate the relative quality of the models, selecting the ones with best goodness of fit. Data 115 
processing and analysis were performed with the statistical software system Stata (StataCorp. 2017. 116 
Stata Statistical Software: Release 15. College Station, TX: StataCorp LLC).  117 
 118 
RESULTS 119 
Clinical characteristics 120 
Between August 2001 and February 2018, 124 patients were included for analysis. This 121 
population accounted for the 3-7% of all anatomical lung resections performed in the different centers. 122 
Seventy-two patients (58.1%) were males, mean age was 60 (SD:9.8) years. Adenocarcinoma was the 123 
most common histology, identified in 87 patients (70.2%), followed by squamous-cell carcinoma in 18 124 
(14.5%) and large-cell carcinoma in 8 (6.4%). Molecular analysis were performed routinely after 2012 125 
and in 20% of patients, some driver mutations were found (EGFR, ALK; KRAS mutation, PDL-1 126 
overexpression, rare mutations). The majority of patients (74%) had advanced intra-thoracic disease (T 127 
and N parameters). Fifty-six patients (45.2%) were N0 at pathological examination, while 23 (18.5%) 128 
and 44 (35.5%) had pN1 and pN2, respectively. Seventy-six (61.3%) had brain metastasis, which was 129 
the most common site, while 13 patients (10.4%) had adrenal metastasis, 12 (9.7%) had bone 130 
localizations and 8 (6.3%) had contralateral lung nodules. All lung metastasis were single contralateral 131 
nodules. The diagnosis of synchronous metastasis was formulated based on pathology (morphology and 132 
mutational status when available) after resection in all of them but one (diagnosis based on CT 133 
morphology and treated with radiotherapy).Overall, 96 patients (77.4%) had a single metastasis and the 134 
vast majority 97.6% had a single organ involved. Only 3 patients had two organs involved by metastasis. 135 
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Regarding the pre-operative staging, all patients underwent PET scan and 36% underwent invasive 136 
mediastinal staging (either EBUS or mediastinoscopy) based on imaging results. 137 
Treatment variables 138 
Thirty-seven patients received neo-adjuvant therapies, in 57 patients initial treatment was on the 139 
metastatic sites, 30 patients underwent lung resection as first. The median interval between the treatment 140 
of the primary tumor and the metastatic sites was 39 day (Interquartile Range: 63 days) in both cases 141 
(metastasis first vs primary first). Treatment of the primary tumor was surgery for all patients, including 142 
lobectomies (n=90), pneumonectomies (n=11), segmentectomies (n=11) and extended resections 143 
(n=12). Radical mediastinal lymphadenectomy was performed in all patients with one exception. 144 
Minimally invasive approach (VATS) was used in 27 patients (22%) for resection of the primary tumor 145 
and in all the 7 patients in whom the lung metastasis were treated with surgery. There was no in-hospital 146 
mortality and the 90-day mortality was 2.4%. Clear resection margins (R0) were obtained in 108 cases 147 
(88.5%). Thirty-seven patients (29.9%) received neo-adjuvant treatment in form of chemotherapy (35, 148 
28.8%) or chemo-radiotherapy (2, 1.6%). General recommendation for advanced intrathoracic stages 149 
included bimodal (surgery/chemotherapy) or trimodal treatments (surgery/chemotherapy/radiotherapy). 150 
Metastases were treated with surgical resection in 46 cases (37.1%), with radiotherapy in 35 (28.2%) 151 
and with a combination of both in 42 patients (35%). One patient had a liver metastasis treated with 152 
radiofrequency ablation. 153 
Sixty-four (51.6%) patients received adjuvant treatments with different combinations including 154 
immunotherapy in 14 cases. With regards of chemotherapy, used alone or in combination with 155 
radiotherapy, or immunotherapy in 46 patients, the most common scheme included a platinum agent 156 
used with doublets or triple-drug regimens. Population and treatments characteristics are expressed in 157 
Table 1. 158 
Overall survival results 159 
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Median follow-up time calculated with reverse Kaplan-Meyer was 60 months (95% confidence 160 
interval (CI): 41, 86). OS at 1-, 2-, 3- and 5-years was 80%, 58%, 49% and 36% respectively (Figure 161 
1A). 162 
Cox regression analysis showed that age ≤60 years, nodal status and bone locations for 163 
metastasis significantly influenced the survival. To avoid collinearity, two separate Cox regression 164 
models were calculated for pN0 status vs pN1-2 and for pN0-1 vs pN2. In both cases, all the tested 165 
variables remained statistically significant, but the AIC analysis showed a better goodness of fit of the 166 
first model (370 vs 377). Therefore, the final model showed that age ≤60 years (HR: 0.41, 95% CI: 0.24, 167 
0.69, p=0.001) and negative pathological mediastinal lymph node status (HR: 0.38, 95% CI: 0.21, 0.69, 168 
p=0.002) remained strongly associated with good prognosis. The presence of bone metastasis negatively 169 
affected survival in the same model (HR: 2.53, 95% CI: 1.05, 6.09, p=0.04). Results are expressed in 170 
Tables 2 and 3. Figure 2 represents the survival curves according to nodal status. 171 
Progression-free survival results 172 
Median PFS time was 11 months (95% CI: 8, 13). PFS survival at 1-, 2-, 3- and 5-years was 173 
41%, 29%, 25% and 23%, respectively. Two Cox models were constructed including separately pN0 vs 174 
1-2 and pN1-2 vs N0. The Cox regression analysis indicated that negative nodal status (HR: 0.38, 95% 175 
CI: 0.41, 0.10, p<0.001) and the presence of bone metastasis (HR: 1.88, 95% CI: 1.06, 3.34, p=0.03) 176 
remained independently associated with the outcome. The model including the groups pN0-1 vs 2 177 
showed to have worst goodness of fit compared with the one displaced (AIC: 508 vs 514). Results of 178 
the analysis are expressed in Tables 4 and 5. 179 
Subgroup analysis 180 
During the follow-up time, 92 patients (74.1%) experienced a recurrence. Only 8 recurrences 181 
(8.7%) were pure loco-regional (lung and/or mediastinal lymph nodes). Most of the patients (84, 68%) 182 
had distant recurrence with or without lung recurrence.  183 
Seventy-nine patients received further treatments, either local and/or systemic after the first progression. 184 
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Within our population with age ≤60 years and nodal status pN0, we counted 28 patients. OS at 185 
1- and 5-year were 100% and 83% respectively (Figure 1B). Twenty patients had brain metastasis 186 
(71.4%) while only one had a bone localization. One patient had a single pleural lesion, 4 had adrenal 187 
metastasis and 2 had lung nodules. In 21 cases (75%) the metastatic site was treated with surgery with 188 
(10 patients) or without the use of radiotherapy boost on the surgical field. Fourteen patients (50%) 189 
experienced a recurrence during the follow-up. Median PFS was 40 months (range: 8-137 months). All 190 
patients had further treatments after first progression. 191 
 192 
DISCUSSION 193 
Our results support aggressive surgical treatment of oligometastatic NSCLC in a context of 194 
curative strategies with 5 year OS of 35% for all, and 83% for younger patients in absence of lymph 195 
node involvement.  196 
The literature on treatment of stage IV lung cancer is heterogeneous, with inconsistent 197 
definitions of “oligometastatic” status, type of treatment administered, populations included and 198 
outcome description. In a systematic review published in 2013(10), aiming to define the oligometastatic 199 
state of NSCLC, the reported 5-year OS for patients treated with curative intent was ranging from 8.3% 200 
to 86%. However, even with such a wide range of prognosis, the control of the primary tumor was 201 
considered highly influencing the survival. A study designed as propensity score analysis comparing 202 
180 patients with synchronous single organ metastasis who received local ablative treatment of all 203 
disease sites versus palliative treatment(11), showed a median OS of 60 months in the first group and a 204 
22.5 months OS in the control group. 205 
As regards the best treatment for primaries, large epidemiological databases analyses have been 206 
recently published. The first one(12), based on data extracted from the National Cancer Database, 207 
considered a population of over 3.000 patients who underwent lung resection for stage IV NSCLC. It 208 
reported a 5-year OS of 21.1%, recommending surgical resection for tumors staged T1-2,N0-1,M1 or 209 
T3,N0,M1. The second large population-based study was based on the Surveillance, Epidemiology and 210 
End Results database(13). This retrospective analysis was conducted on over 39.000 cases of stage IV 211 
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NSCLC, of which 1206 underwent surgical resection of primary tumor. The authors found that primary 212 
tumor resection was associated with significantly longer OS in different cohorts of patients. Other 213 
clinical and epidemiological studies, favored surgery for the primary site as cornerstone treatment of 214 
oligometastatic NSCLC(14-17). 215 
We focused our analysis on patients undergoing lung resection and local radical treatment for 216 
metastatic sites. Overall, our population was younger than the average of NSCLC patients, and, possibly 217 
in good clinical conditions, particularly, the best results in terms of survival have been obtained in 218 
younger patients (≤60 years). Indication for anatomical lung resections is usually discussed in 219 
multidisciplinary settings, and operability criteria, such as respiratory reserve and cardiac risk are part 220 
of the decision-making process. In our cohort, we did not have information on performance status, but 221 
we can assume that, as surgical candidates, it was less than 2 in all patients. 222 
Other studies reported that age and performance status influence the prognosis. Ampil(18), in a 223 
series of 72 cases, found that patients with solitary metastasis younger than 65 years had a longer 224 
survival compared to the older counterpart. It is intuitive, that patients in better general conditions are 225 
more prone to be included in aggressive treatment programs. As an example, the study of Frost(11), 226 
analyzed 107 patients who received local ablative treatments for synchronous single organ metastatic 227 
lung cancer, comparing them with 266 patients who did receive palliative treatments. Good performance 228 
status was strongly associated with better survival within the control group and remained associated 229 
with good outcome after propensity score matching of groups. In our series, age ≤60 years correlated 230 
with OS but not with PFS: these results, along with the published literature, generally indicate that 231 
patients in good clinical conditions could possibly be selected for upfront aggressive treatments and for 232 
further therapies after first progression. 233 
The other factor strongly associated with OS and PFS in our study was the negative nodal status 234 
of the primary tumor. These results are in line with most published reports, either from clinical series 235 
and analysis of epidemiological databases(10,11,15,19,22). A large patient data meta-analysis(20) 236 
identified a subgroup of patients classified as “intermediate” risk with synchronous metastasis and 237 
negative nodes. Those patients exhibited a 5-year OS of 36.2% in the training set and 29.2% in the 238 
validation set, while patients considered as “high risk”, with synchronous metastasis and N≥ 1, had a 5-239 
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year OS of 13.8%. These results are superimposable with our own data. The 2018 European Society for 240 
Medical Oncology(2) guidelines also mention these groups definition. The National Comprehensive 241 
Cancer Network guidelines(3) suggest that in patients who have single brain or adrenal metastases, and 242 
a primary tumor that is T1-2/N0-1 or T3/N0, the management should include local treatment of the 243 
metastasis followed by resection of the lung lesion, in combination with chemotherapy either before or 244 
after lung resection. The National Cancer Database analysis performed by Yang(12), supporting these 245 
assertions, showed a 5-year OS of 28.8% for stages T1-2/N0, 20.5% for stage T3-4/N0 and 17.4 for 246 
stage T1-2/N1, leading to some conflicting interpretations. 247 
Possibly, the difference in survival between N0 and N-positive patients reflects the parallel patterns of 248 
tumor spread through hematogenous and lymphatic pathways, which can affect the results in terms of 249 
local thoracic disease control. 250 
 Although the median OS in our series was 36 months, a proportion of patients progressed locally 251 
or distantly after treatment with a median PFS of 11 months. The factors negatively associated with 252 
progression were nodal involvement and presence of bone metastasis. 253 
In our subgroup ≤60 years and N0, the 5-year OS was 83%. This result does not translate in a 254 
curative treatment for all patients. Indeed, 50% of patients experienced a recurrence, with a median PFS 255 
time of 40 months, with a consistent difference with the overall population, who had a median PFS time 256 
of 11 months. This introduces the concept of possible identification of indolent disease, rather than truly 257 
eradicated cancers. Again, the young age of the patients might have conditioned the proposal and 258 
acceptance of further treatments after first progression, which has been 100% in all recurrent cases in 259 
our best sub-group. In general, the majority of patients received additional therapies for recurrent disease 260 
with redo surgery for brain metastasis, radiation therapy, chemotherapy or target/immunotherpies. These 261 
data, along with the difference between the OS and the PFS, indicates that good candidates might benefit 262 
from aggressive treatments and “rescue” therapies in selected cases. New alternative strategies as 263 
ultraguided ablative techniques may further improve the outcome. 264 
Because of the design of our study, based on a surgical population, we can draw two 265 
considerations: we did not include any N3 patient who did not candidate for lung resection, and our 266 
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analysis considered the pathological staging. The latter point might be a limit of the study, as it does not 267 
offer pre-treatment indications, which are mandatory in the real world. On the other hand, results are 268 
adherent with the true stage of the disease. Based on this assumption, we strongly recommend invasive 269 
nodal staging for all patients considered for lung resection of oligometastatic NSCLC. Another limit of 270 
our study is its retrospective design. Including patients treated more than a decade ago allowed a long 271 
follow-up, but included heterogeneous surgical and oncological therapies. Immunotherapy was 272 
administered to few patients, possibly biasing its impact on the prognosis of these patients knowing to 273 
benefit from it. Moreover, a long follow-up offers a good overview on patients’ survival, but introduces 274 
a bias due to deaths not related to cancer diagnosis. In fact, usual lung cancer patients are life-longing 275 
smokers and present many comorbidities. Our population has a selection-bias compared to the general 276 
patients with stage IV NSCLC, and without a control group, it is difficult to ascertain whether the 277 
treatment solely, rather than patient selection, has led to positive outcome. Being a surgical population, 278 
some patients’ characteristics are not truly representative of the general stage IV patients. As an 279 
example, the mean age of our cohort is quite low, the performance status and the general clinical 280 
conditions must have been high and the burden of disease was surely low. All these considerations must 281 
be taken into account when looking at the results. Indeed, our results may reflect an "improved selection 282 
of winners": the baseline characteristics of the patients justified the choice of aggressive treatments at 283 
first glance and also the use of further treatments after first progression. Selection bias can be noted also 284 
in the number of metastasis and metastatic organs (77.4% had a single metastasis and 97.6% had a single 285 
organ involved). Overall, the number of the patients is limited and, even though the results are 286 
interesting, careful interpretation is mandatory specifically for the subgroup analysis. 287 
Considering the limitations, some conclusions can be made. Surgery for primary lung cancer in 288 
oligometastatic stage IV is confirmed to offer a good prognosis with low morbidity and mortality in 289 
selected patients. The presence of lymph-node involvement confirms to influence both the OS and the 290 
PFS therefore, the candidate selection process should include accurate staging. Even if strong 291 
conclusions cannot be drawn from a retrospective analysis of less than 200 cases, the encouraging results 292 
might help in the decision-making process during multidisciplinary discussion and patients counselling. 293 
It is worth to investigate further prognostic factors, possibly including genetics and biomarkers that 294 
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might refine clinical indicators for patient selection and that might help to identify NSCLCs with 295 
different clinical and biological behavior. Finally, it is notable that even in case of nodal involvement, 296 
the results showed in our series are acceptable. In the era of immuno- and target-therapies, this might 297 
open to synergic strategies including surgery, in order to reduce the mutational tumor burden, even in 298 
more advanced cases. 299 
  300 
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Figure 1: Survival curves for the entire population (A) and for patients ≤60 years and N0 (B). Median 305 
OS starting from primary tumor resection was 34 months (95% CI: 22-51) 306 
Figure 2: Survival curves for patients with N0 vs N1-2 307 
 308 
 309 
  310 
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Table 1: Population and treatments characteristics 311 
Population 124 
GENERAL VARIABLES  
Male gender 72 (58.1%) 
Age (mean, SD) 60 , 9.8 
Histology  
Adenocarcinoma 87 (70.2%) 
Squamous Cell Carcinoma 18 (14.5%) 
Large Cell Carcinoma 8 (6.4%) 
Neuroendocrine 3 (2.4%) 
Other 8 (6.4%) 
  
PRIMARY VARIABLES  
T-descriptor (UICC VII)  
pTx 2 (1.6%) 
pT1 22 (17.7%) 
pT2 53 (42.7%) 
pT3 37 (29.8%) 
pT4 10 (8.1%) 
N-descriptor  
pNx 1 (1%) 
pN0 56 (45.2%) 
pN1 23 (18.5%) 
pN2 44 (35.5%) 
  
METASTASIS VARIABLES  
Mets location  
Brain 76 (61.3%) 
Adrenal 13 (10.4%) 
Bone 12 (9.7%) 
Lung 8 (6.3%) 
Other 12 (9.6%) 
Multiple locations 3 (2.4%) 
Single metastasis 96 (77.4%) 
Single organ involved 121 (97.6%) 
  
TREATMENT VARIABLES  
Neoadjuvant 37 (29.9%) 
   CHT 35 (28.2%) 
   CHT/RT 2 (1.6%) 
Treatment for primary  
   Surgery 124 (100%) 
   R0 (surgical margins primary) 108 (88.5%) 
   30-day mortality 0 
Treatment for mets  
   Surgery 46 (37.1%) 
   RT 35 (28.2%) 
   Combined 42 (35%) 
   Other 1 (1%) 
Adjuvant 64 (51.6%) 
   CHT 40 (32.2%) 
   CHT/RT 2 (1.6%) 
16 
 
   Immunotherapy 7 (5.6%) 
   CHT/immunothearpy 3 (2.4%) 
   RT 8 (6.4%) 
   RT/immunotherapy 6 (4.8%) 
   Immunotherapy/RT/CHT 1 (1%) 
  
RECURRENCE 92 (74.1%) 
Type of recurrence  
Loco-regional (lung and lymph-nodes) 8 (8.7%) 
Local mets recurrence 35 (38%) 
Treatment of recurrence 78 (84.8%) 
Treatment with curative intent 11 (12%) 
Type of treatment  
   Surgery 15 (16.3%) 
   RT 22 (23.9%) 
   CHT 9 (9.8%) 
   Immunotherapy 12 (14.1%) 
   Combined 20 (21.7%) 
 312 
  313 
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Table 2: Results of Cox regression analysis for overall survival 314 
Variable HR 95% CI p-value 
Age ≤ 60 vs >60 0.41 0.24, 0.69 0.001 
pN0 vs 1-2 0.38 0.21, 0.69 0.002 
Mets location    
   Bone vs other 2.53 1.05, 6.09 0.04 
   Lung vs other 0.18 0.02, 1.45 0.1 
 315 
  316 
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CI (2 years) Survival 
function 
at 5 years 
CI (5 years) Log-rank 
pN0 78 76 0.61, 0.84 61 0.45, 0.75 
<0.001 
pN1-2 20 44 0.31, 0.56 16 0.07, 0.29 
Age ≤60 y 54 69 0.55, 0.80 45 0.29, 0.59 
0.002 
Age >60 y 22 46 0.33, 0.59 27 0.14, 0.41 
Bone mets 12 16 0.01, 0.49 NR - 
<0.001 
Other sites 39 61 0.51, 0.70 39 0.29, 0.50 
NR: not reached 318 
  319 
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Table 4: Results of Cox regression analysis for progression-free survival 320 
Variable HR 95% CI p-value 
Metastasis first 0.59 0.34, 1.04 0.09 
pN0 vs 1-2 0.38 0.41, 0.10 <0.001 
Mets location    
   Bone vs other 1.88 1.06, 3.34 0.03 
   Brain vs other 2.02 0.87, 4.74 0.1 
 321 
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CI (2 years) Survival 
function 
at 5 years 
CI (5 years) Log-rank 
pN0 24 48 0.34, 0.62 37 0.23, 0.52 
<0.001 
pN1-2 8 15 0.07, 0.25 11 0.04, 0.22 
Bone mets 3 NR - NR - 
0.03 
Other sites 11 31 0.23, 0.40 24 0.16, 0.33 
NR: not reached 
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